Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2005-04-26
2005-04-26
Spector, Lorraine (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S085100, C424S198100, C435S069700, C435S069500, C530S351000
Reexamination Certificate
active
06884419
ABSTRACT:
The present invention relates to a fusion polypeptide which comprises a polypeptide having G-CSF activity and a polypeptide having TPO activity and DNA which codes for the fusion polypeptide, to a fusion polypeptide in which a polypeptide having G-CSF activity and a polypeptide having TPO activity are fused via a spacer peptide and DNA which codes for the fusion polypeptide and to a polypeptide in which the fusion polypeptide comprising a polypeptide having G-CSF activity and a polypeptide having TPO activity is chemically modified with a polyalkylene glycol derivative. It also relates to an anemia-treating composition containing the fusion polypeptide as an active ingredient.
REFERENCES:
patent: 4999291 (1991-03-01), Souza
patent: 5073627 (1991-12-01), Curtis et al.
patent: 5641655 (1997-06-01), Foster et al.
patent: 5989537 (1999-11-01), Holly et al.
patent: 0335423 (1989-03-01), None
patent: 0 335 423 (1989-10-01), None
patent: 0544292 (1992-11-01), None
patent: A-4-103599 (1992-04-01), None
patent: WO 9012877 (1990-11-01), None
patent: WO9204455 (1992-03-01), None
“Cytokines”, A. Mire-Sluis et al., ed., Academic Press, San Diego, 1998. pp. 237-238, 330-331.*
Janis Kuby, “Immunology”, W.H. Freeman and Company, NY, 1992, pp. 42 and 44.*
Frederick J. de Sauvage et al “Stimulation of Megakaryocytopoiesis and Thrombopoiesis by the C-MPL Ligand” Nature (1994) vol. 369, pp 533-538.
Callard et al The Cytokine Facts Book 1994 pp 46 etc.
Paul et al Proc. Natl. Acad. Sci. vol. 87 pp 7512-7516 10/90 Genetics Molecular Cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytoking.
Rock et al Protein Engineering vol. 5 No. 6 pp 584-591, 1992, pp 583-591 Overexpression an structure—function analysis of a bioengineered II-21L-6 chimeric lymphokine.
Gillies et al Bioconjugate Chem. 1993, p 230-235 Biological Activity and in Vivo Clearance of Antitumor etc.
Feng et al Reports 9/88 pp 1501-1503 Antiproliferative Activity of a Hybrid Protein between Interferon-γ etc.
Mikayama et al Proc. Natl. Acad. Sci. USA vol. 90 pp 10056-10060.
Voet et al Biochemistry, John Wiley & Sons, Inc. pp 126-128 and 228-234.
Cuningham et al (1989) Science, vol. 244, pp 1081-1085.
George et al (1988) Molecular Sequencing & Synthesis chapter 12, pp 127-149 Alan R. Liss, Inc. New York.
Anazawa Hideharu
Kato Yoko
Konishi Noboru
Shiotsu Yukimasa
Tamaoki Tatsuya
Kyowa Hakko Kogyo Co. Ltd.
Nixon & Vanderhye P.C.
Spector Lorraine
LandOfFree
hG-CSF fusion polypeptide having c-mpl activity, DNA coding... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with hG-CSF fusion polypeptide having c-mpl activity, DNA coding..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and hG-CSF fusion polypeptide having c-mpl activity, DNA coding... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3395936